研究概要
肝细胞癌(HCC)是肝癌的主要亚型,由于诊断晚、进展快,治疗面临重大挑战。
中文摘要
肝细胞癌(HCC)是肝癌的主要亚型,由于其诊断晚、进展快,带来了重大的治疗挑战。免疫治疗领域的不断发展带来了一线希望,其中自然杀伤(NK)细胞正成为抗击 HCC 的关键角色。NK 细胞是独特的细胞毒性淋巴细胞,在对抗感染和恶性肿瘤中至关重要。HCC 患者中已显示出 NK 细胞的表型和功能异常,表明其作为固有免疫系统抗肿瘤组成部分的重要性。本综述阐明了 NK 细胞在抗击 HCC 中的关键作用,重点关注其与肿瘤微环境的相互作用、基于 NK 细胞的疗法的发展,以及在 HCC 免疫抑制环境中增强其疗效的创新策略。本综述深入探讨了各种治疗策略,包括自体 and 异体 NK 细胞疗法、提高 NK 细胞适应性和靶向性的基因工程,以及 NK 细胞与其他免疫治疗方法(如检查点抑制剂和溶瘤病毒疗法)的整合。通过强调该领域的近期进展和持续挑战,本综述为未来的研究方向奠定了基础,这些方向可能释放基于 NK 细胞的免疫疗法治疗 HCC 的全部潜力,为与这一严峻癌症作斗争的患者带来一线希望。
展开英文摘要原文
Hepatocellular carcinoma (HCC), a major subtype of liver cancer, poses significant therapeutic challenges due to its late diagnosis and rapid progression. The evolving landscape of immunotherapy offers a beacon of hope, with natural killer (NK) cells emerging as pivotal players in combating HCC. NK cells are unique cytotoxic lymphocytes that are essential in the fight against infections and malignancies. Phenotypic and functional NK cell abnormalities have been shown in HCC patients, indicating their significance as a component of the innate immune system against cancer. This review elucidates the critical role of NK cells in combating HCC, focusing on their interaction with the tumor microenvironment, the development of NK cell-based therapies, and the innovative strategies to enhance their efficacy in the immunosuppressive milieu of HCC. The review delves into the various therapeutic strategies, including autologous and allogeneic NK cell therapies, genetic engineering to improve NK cell resilience and targeting, and the integration of NK cells with other immunotherapeutic approaches like checkpoint inhibitors and oncolytic virotherapy. By highlighting recent advancements and the ongoing challenges in the field, this review sets the stage for future research directions that could unlock the full potential of NK cell-based immunotherapy for HCC, offering a beacon of hope for patients battling this formidable cancer.
论文信息
- 作者
- Wang X、Yang T、Shi X
- 第一作者单位
- The First Clinical Medical College, Nanjing Medical University, Nanjing, Jiangsu Province 210009, China.China
- 通讯作者单位
- Hepatobiliary/Liver Transplantation Center, The First Affiliated Hospital of Nanjing Medical University, Key Laboratory of Living Donor Transplantation, Chinese Academy of Medical Sciences, Nanjing, Jiangsu Province 210029, China; Department of General Surgery, The Affiliated Drum Tower Hospital of Nanjing University Medical School, Nanjing, China. Electronic address: 230219044@seu.edu.cn.China
- 文献类型
- 综述
- 期刊
- Cellular signalling2024 Dec